by Brent P. Forester, MD, MSc, Joseph F. Goldberg, MD, Charles F. Reynolds, III, MD
While the Montreal Cognitive Assessment (MoCA) is recommended in the primary care setting as a screening tool for cognitive impairment, the optimal......READ MORE
by Brent P. Forester, MD, MSc, Charles F. Reynolds, III, MD, Michael E. Thase, MD
Improving quality of life for a patient with major depressive disorder (MDD) requires clinicians to first recognize the depression. Such recognitio......READ MORE
by Charles Debattista, MD, Ira D. Glick, MD, Roger McIntyre, MD, Madhukar Trivedi, MD
There is growing recognition that cognitive dysfunction in major depressive disorder (MDD) has been relatively overlooked by clinicians, academic r......READ MORE
by Charles Debattista, MD, Ira D. Glick, MD, Roger McIntyre, MD, Madhukar Trivedi, MD
Cognitive disturbances certainly overlap with emotional and somatic symptoms in patients with major depressive disorder (MDD), and improvements in ......READ MORE
How much is truly known about antidepressants and cognition, and are strategies for selecting antidepressants formulated with careful consideration......READ MORE
by Charles Debattista, MD, Roger McIntyre, MD, Madhukar Trivedi, MD
How feasible would it be to implement a point-of-care screening tool, or symptom-monitoring tool, to measure cognition in depressed patients? While......READ MORE
